<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="jah310564" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id><journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id><journal-id journal-id-type="pmc-domain-id">1888</journal-id><journal-id journal-id-type="pmc-domain">jaha</journal-id><journal-id journal-id-type="publisher-id">JAH3</journal-id><journal-title-group><journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title></journal-title-group><issn pub-type="epub">2047-9980</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12229217</article-id><article-id pub-id-type="pmcid-ver">PMC12229217.1</article-id><article-id pub-id-type="pmcaid">12229217</article-id><article-id pub-id-type="pmcaiid">12229217</article-id><article-id pub-id-type="pmid">40401606</article-id><article-id pub-id-type="doi">10.1161/JAHA.124.038589</article-id><article-id pub-id-type="publisher-id">JAH310564</article-id><article-id pub-id-type="other">JAHA/2024/038589</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="heading"><subject>Coronary Heart Disease</subject></subj-group></subj-group></article-categories><title-group><article-title>Contemporary Use and Clinical Significance of Initial Triple Versus Double Therapy After Percutaneous Coronary Intervention for Myocardial Infarction in Patients With Atrial Fibrillation</article-title><alt-title alt-title-type="right-running-head">Initial Triple vs Double Therapy After <styled-content style="fixed-case" toggle="no">PCI</styled-content> in <styled-content style="fixed-case" toggle="no">AF</styled-content></alt-title><alt-title alt-title-type="left-running-head">Park et&#160;al</alt-title></title-group><contrib-group><contrib id="jah310564-cr-0001" contrib-type="author"><name name-style="western"><surname>Park</surname><given-names initials="DY">Dae Yong</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1486-7452</contrib-id><xref rid="jah310564-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jah310564-cr-0002" contrib-type="author"><name name-style="western"><surname>McLean</surname><given-names initials="B">Bianca</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9141-525X</contrib-id><xref rid="jah310564-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jah310564-cr-0003" contrib-type="author"><name name-style="western"><surname>Akman</surname><given-names initials="Z">Zafer</given-names></name><degrees>MD</degrees><xref rid="jah310564-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jah310564-cr-0004" contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="DK">Darrick K.</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1983-0165</contrib-id><xref rid="jah310564-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="jah310564-cr-0005" contrib-type="author"><name name-style="western"><surname>Babapour</surname><given-names initials="G">Golsa</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-5018-3099</contrib-id><xref rid="jah310564-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jah310564-cr-0006" contrib-type="author" corresp="yes"><name name-style="western"><surname>Nanna</surname><given-names initials="MG">Michael G.</given-names></name><degrees>MD, MHS</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5745-1636</contrib-id><xref rid="jah310564-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>michael.nanna@yale.edu</email></address></contrib></contrib-group><aff id="jah310564-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Section of Cardiovascular Medicine</named-content>
<institution>Yale School of Medicine</institution>
<city>New Haven</city>
<named-content content-type="country-part">CT</named-content>
<country country="US">USA</country>
</aff><aff id="jah310564-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>Yale School of Medicine</institution>
<city>New Haven</city>
<named-content content-type="country-part">CT</named-content>
<country country="US">USA</country>
</aff><aff id="jah310564-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Section of Digestive Diseases</named-content>
<institution>Yale School of Medicine</institution>
<city>New Haven</city>
<named-content content-type="country-part">CT</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label>
Correspondence to: Michael G. Nanna, MD, MHS, Department of Medicine, Section of Cardiovascular Medicine, Yale School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA. Email: <email>michael.nanna@yale.edu</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><day>03</day><month>6</month><year>2025</year></pub-date><volume>14</volume><issue seq="50">11</issue><issue-id pub-id-type="pmc-issue-id">492312</issue-id><issue-id pub-id-type="doi">10.1002/jah3.v14.11</issue-id><elocation-id>e038589</elocation-id><history><date date-type="received"><day>28</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>23</day><month>12</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>05</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>07</day><month>07</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-07 10:25:51.900"><day>07</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="JAH3-14-e038589.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:JAH3-14-e038589.pdf"/><abstract><sec id="jah310564-sec-0001"><title>Background</title><p>Patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI) have traditionally received triple therapy (dual antiplatelet therapy and anticoagulation). More recent randomized trial evidence supports a strategy of double therapy (anticoagulant plus single antiplatelet agent), albeit after a brief triple therapy course. The safety of initiating double therapy immediately post&#8208;PCI remains unclear.</p></sec><sec id="jah310564-sec-0002"><title>Methods and Results</title><p>This study analyzed real&#8208;world prescribing patterns and outcomes of immediate double therapy versus initial triple therapy in patients with atrial fibrillation post&#8208;PCI using the Vizient Clinical Database. Patients with atrial fibrillation undergoing PCI for myocardial infarction (2016&#8211;2023) were categorized into 2 groups: triple therapy (aspirin, P2Y12 [purinergic receptor P2Y, G&#8208;protein coupled, 12 protein] inhibitor, and anticoagulant) or double therapy (anticoagulant and 1 antiplatelet agent) on day 1 post&#8208;PCI. The primary outcome was in&#8208;hospital mortality. Secondary outcomes included stent thrombosis, major bleeding, intracranial hemorrhage, and net clinical adverse events. Multivariable logistic regression and inverse probability of treatment weighting were used to compare outcomes. Among 29&#8201;226 patients, 16.3% received immediate double therapy on day 1 post&#8208;PCI, whereas 83.7% received triple therapy. Adjusted analyses showed no significant differences in in&#8208;hospital mortality (9.4% versus 9.2%, adjusted odds ratio [aOR], 1.05 [95% CI, 0.93&#8211;1.18]), major bleeding, intracranial hemorrhage, or net clinical adverse events. However, immediate double therapy was associated with higher odds of stent thrombosis (1.1% versus 0.8%; aOR, 1.48 [95% CI, 1.08&#8211;2.03]), particularly in patients with ST&#8208;segment&#8211;elevation myocardial infarction (2.0% versus 1.3%; aOR, 1.46 [95% CI, 1.001&#8211;2.13]).</p></sec><sec id="jah310564-sec-0003"><title>Conclusions</title><p>Immediate double therapy post&#8208;PCI is frequently used and appears safe for most patients with atrial fibrillation. Further studies are needed to identify high&#8208;risk subgroups, including those with ST&#8208;segment&#8211;elevation myocardial infarction, who may benefit from an initial short course of triple therapy.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jah310564-kwd-0001">anticoagulant</kwd><kwd id="jah310564-kwd-0002">antiplatelet</kwd><kwd id="jah310564-kwd-0003">atrial fibrillation</kwd><kwd id="jah310564-kwd-0004">myocardial infarction</kwd><kwd id="jah310564-kwd-0005">pharmacotherapy</kwd></kwd-group><kwd-group kwd-group-type="subject-categories"><title>Subject Categories</title><kwd>Myocardial Infarction</kwd><kwd>Chronic Ischemic Heart Disease</kwd><kwd>Atrial Fibrillation</kwd></kwd-group><counts><fig-count count="1"/><table-count count="2"/><page-count count="7"/><word-count count="4200"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>03 June 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.7 mode:remove_FC converted:23.06.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="jah310564-ntgp-0001"><fn id="jah310564-note-0001"><p>This article was sent to Rushi V. Parikh, MD, Associate Editor, for review by expert referees, editorial decision, and final disposition.</p></fn><fn id="jah310564-note-0002"><p>Supplemental Material is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/JAHA.124.038589" ext-link-type="uri">https://www.ahajournals.org/doi/suppl/10.1161/JAHA.124.038589</ext-link>
</p></fn><fn id="jah310564-note-0003"><p>For Sources of Funding and Disclosures, see page 7.</p></fn></fn-group></notes></front><body id="jah310564-body-0001"><def-list list-content="abbreviations" id="jah310564-dl-0001"><title>Nonstandard Abbreviations and Acronyms</title><def-item><term id="jah310564-li-0001">ICH</term><def id="jah310564-li-0002"><p>intracranial hemorrhage</p></def></def-item><def-item><term id="jah310564-li-0003">IPTW</term><def id="jah310564-li-0004"><p>inverse probability of treatment weighting</p></def></def-item><def-item><term id="jah310564-li-0005">NACE</term><def id="jah310564-li-0006"><p>net clinical adverse events</p></def></def-item><def-item><term id="jah310564-li-0007">P2Y12</term><def id="jah310564-li-0008"><p>purinergic receptor P2Y, G&#8208;protein coupled, 12 protein</p></def></def-item><def-item><term id="jah310564-li-0009">TIMI</term><def id="jah310564-li-0010"><p>Thrombolysis In Myocardial Infarction</p></def></def-item></def-list><p>
<boxed-text position="anchor" content-type="box" id="jah310564-blkfxd-0001" orientation="portrait"><caption><title>Research Perspective</title></caption><sec id="jah310564-sec-0006"><title>What New Question Does This Study Raise?</title><p>
<list list-type="bullet" id="jah310564-list-0001"><list-item id="jah310564-li-0011"><p>Over 15% of patients with atrial fibrillation undergoing percutaneous coronary intervention are transitioned immediately to double therapy, bypassing a short course of triple therapy.</p></list-item><list-item id="jah310564-li-0012"><p>Immediate double therapy has comparable safety to triple therapy in regard to in&#8208;hospital mortality and bleeding but is associated with a higher risk of stent thrombosis, particularly in patients with ST&#8208;segment&#8211;elevation myocardial infarction.</p></list-item></list>
</p></sec><sec id="jah310564-sec-0007"><title>What Question Should Be Addressed Next?</title><p>
<list list-type="bullet" id="jah310564-list-0002"><list-item id="jah310564-li-0013"><p>Future randomized trials are needed to determine which patients with atrial fibrillation require an initial short course of triple therapy before transitioning to double therapy post&#8208;percutaneous coronary intervention and, if so, to establish the optimal duration.</p></list-item></list>
</p></sec></boxed-text>
</p><p>Atrial fibrillation (AF) increases the risk of in&#8208;hospital morbidity and mortality in patients undergoing percutaneous coronary intervention (PCI).<xref rid="jah310564-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="jah310564-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Historically, patients with AF who undergo PCI were treated with dual antiplatelet therapy and anticoagulation, known as triple therapy. However, triple therapy increases bleeding risk, and multiple randomized trials have since shown the superiority of double therapy (anticoagulant plus single antiplatelet therapy) over triple therapy with regard to safety profile.<xref rid="jah310564-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Notably, these trials mandated a short duration of triple therapy before dropping the second antiplatelet agent in the double therapy arm.<xref rid="jah310564-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="jah310564-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="jah310564-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="jah310564-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> For example, landmark randomized trials investigating double versus triple therapy in this population transitioned from triple to double therapy anywhere from 6 to 30&#8201;days after PCI.<xref rid="jah310564-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="jah310564-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="jah310564-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="jah310564-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Given this heterogeneity, there is no current consensus on how long to wait before transitioning from triple to double therapy after PCI.<xref rid="jah310564-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="jah310564-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="jah310564-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="jah310564-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Some clinicians may skip this short course of triple therapy and immediately transition to double therapy post&#8208;PCI, despite the lack of randomized trial evidence supporting this practice. The prevalence and safety of this untested approach are unknown. We aimed to use real&#8208;world data to understand the in&#8208;hospital prescribing patterns and clinical impact of immediate double therapy versus an initial course of triple therapy in patients with AF post&#8208;PCI.</p><sec sec-type="methods" id="jah310564-sec-0008"><title>METHODS</title><sec id="jah310564-sec-0009"><title>Data Source</title><p>The data supporting this study are available from the corresponding author upon reasonable request. We used the Vizient Clinical Database to conduct our retrospective cohort study. In brief, the Vizient Clinical Database gathers patient information on their demographics, medical conditions, laboratory tests, medications, and outcomes from &gt;1000 health care institutions in the United States to assess the quality of care and provide metrics on hospital performance. The tests, medications, and procedures in Vizient are based on what the hospital charged the patient or the insurance company. No informed consent was required. Our study protocol was submitted to our institution and deemed institutional review board exempt. The institutional oversight committee at Vizient also approved the use of their database.</p></sec><sec id="jah310564-sec-0010"><title>Study Population and Covariates</title><p>We identified adults &#8805;18&#8201;years of age with AF who underwent PCI for myocardial infarction from January 1, 2016 to June 30, 2023. PCI was defined as the placement of &#8805;1 intracoronary drug&#8208;eluting stent or bare&#8208;metal stent. For each patient with AF who underwent PCI, we extracted information on his or her demographics, consisting of age, sex, and race. Relevant comorbidities, as shown in Table&#160;<xref rid="jah310564-tbl-0001" ref-type="table">1</xref>, were also characterized. Hospital characteristics, year of encounter, encounter type, and insurance information were also collected. Finally, procedural information on stent type, ballon angioplasty, multivessel intervention, and intravascular imaging was described. All diagnoses and comorbid conditions were ascertained using <italic toggle="yes">International Classification of Disease, Tenth Revision, Clinical Modification</italic> (<italic toggle="yes">ICD&#8208;10&#8208;CM</italic>) codes, and all procedural data were determined using <italic toggle="yes">International Classification of Disease, Tenth Revision, Procedure Coding System</italic> (<italic toggle="yes">ICD&#8208;10&#8208;PCS</italic>) codes. All of the <italic toggle="yes">ICD&#8208;10&#8208;CM</italic> and <italic toggle="yes">ICD&#8208;10&#8208;PCS</italic> codes used in our study are listed in Tables&#160;<xref rid="jah310564-supitem-0001" ref-type="supplementary-material">S1</xref> and <xref rid="jah310564-supitem-0001" ref-type="supplementary-material">S2</xref>.</p><table-wrap position="float" id="jah310564-tbl-0001" content-type="Table" orientation="portrait"><label>Table 1</label><caption><p>Baseline Characteristics of Patients at Index Encounter</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Triple therapy</th><th align="left" rowspan="1" colspan="1">Double therapy</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Patient sample size</td><td align="left" rowspan="1" colspan="1">24&#8201;449</td><td align="left" rowspan="1" colspan="1">4777</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="3" rowspan="1">Clinical presentation</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">ST&#8208;segment&#8211;elevation myocardial infarction, %</td><td align="left" rowspan="1" colspan="1">42.6</td><td align="left" rowspan="1" colspan="1">36.9</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Non&#8211;ST&#8208;segment&#8211;elevation myocardial infarction, %</td><td align="left" rowspan="1" colspan="1">57.4</td><td align="left" rowspan="1" colspan="1">63.1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Demographics</td></tr><tr><td align="left" style="padding-left:10%" colspan="3" rowspan="1">Age group, y, %</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&lt;65</td><td align="left" rowspan="1" colspan="1">25.1</td><td align="left" rowspan="1" colspan="1">22.7</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">65&#8211;74</td><td align="left" rowspan="1" colspan="1">31.4</td><td align="left" rowspan="1" colspan="1">30.8</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">75&#8211;84</td><td align="left" rowspan="1" colspan="1">30.1</td><td align="left" rowspan="1" colspan="1">32.1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#8805;85</td><td align="left" rowspan="1" colspan="1">13.4</td><td align="left" rowspan="1" colspan="1">14.4</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male sex, %</td><td align="left" rowspan="1" colspan="1">67.3</td><td align="left" rowspan="1" colspan="1">67.3</td><td align="left" rowspan="1" colspan="1">0.989</td></tr><tr><td align="left" style="padding-left:10%" colspan="3" rowspan="1">Race, %</td><td align="left" rowspan="1" colspan="1">0.030</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Asian</td><td align="left" rowspan="1" colspan="1">2.1</td><td align="left" rowspan="1" colspan="1">2.2</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Black</td><td align="left" rowspan="1" colspan="1">8.8</td><td align="left" rowspan="1" colspan="1">7.5</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">White</td><td align="left" rowspan="1" colspan="1">81.5</td><td align="left" rowspan="1" colspan="1">82.3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Other<xref rid="jah310564-note-0444" ref-type="table-fn">*</xref>
</td><td align="left" rowspan="1" colspan="1">7.6</td><td align="left" rowspan="1" colspan="1">8.0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Comorbidities</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Smoking, %</td><td align="left" rowspan="1" colspan="1">54.5</td><td align="left" rowspan="1" colspan="1">53.0</td><td align="left" rowspan="1" colspan="1">0.060</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension, %</td><td align="left" rowspan="1" colspan="1">26.3</td><td align="left" rowspan="1" colspan="1">26.1</td><td align="left" rowspan="1" colspan="1">0.834</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes, %</td><td align="left" rowspan="1" colspan="1">47.1</td><td align="left" rowspan="1" colspan="1">48.2</td><td align="left" rowspan="1" colspan="1">0.144</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Dyslipidemia, %</td><td align="left" rowspan="1" colspan="1">73.6</td><td align="left" rowspan="1" colspan="1">75.7</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Obesity, %</td><td align="left" rowspan="1" colspan="1">26.0</td><td align="left" rowspan="1" colspan="1">25.2</td><td align="left" rowspan="1" colspan="1">0.238</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Congestive heart failure, %</td><td align="left" rowspan="1" colspan="1">63.5</td><td align="left" rowspan="1" colspan="1">64.0</td><td align="left" rowspan="1" colspan="1">0.481</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Valvular heart disease, %</td><td align="left" rowspan="1" colspan="1">16.0</td><td align="left" rowspan="1" colspan="1">17.2</td><td align="left" rowspan="1" colspan="1">0.047</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Peripheral artery disease, %</td><td align="left" rowspan="1" colspan="1">5.8</td><td align="left" rowspan="1" colspan="1">6.3</td><td align="left" rowspan="1" colspan="1">0.178</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior PCI, %</td><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">1.7</td><td align="left" rowspan="1" colspan="1">0.444</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior CABG, %</td><td align="left" rowspan="1" colspan="1">11.0</td><td align="left" rowspan="1" colspan="1">12.4</td><td align="left" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior myocardial infarction, %</td><td align="left" rowspan="1" colspan="1">20.6</td><td align="left" rowspan="1" colspan="1">22.5</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior stroke, %</td><td align="left" rowspan="1" colspan="1">16.0</td><td align="left" rowspan="1" colspan="1">19.0</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">COPD, %</td><td align="left" rowspan="1" colspan="1">21.4</td><td align="left" rowspan="1" colspan="1">21.4</td><td align="left" rowspan="1" colspan="1">0.946</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Pulmonary hypertension, %</td><td align="left" rowspan="1" colspan="1">12.6</td><td align="left" rowspan="1" colspan="1">13.8</td><td align="left" rowspan="1" colspan="1">0.025</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Chronic kidney disease, %</td><td align="left" rowspan="1" colspan="1">37.3</td><td align="left" rowspan="1" colspan="1">37.6</td><td align="left" rowspan="1" colspan="1">0.669</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">End&#8208;stage renal disease, %</td><td align="left" rowspan="1" colspan="1">7.4</td><td align="left" rowspan="1" colspan="1">7.5</td><td align="left" rowspan="1" colspan="1">0.682</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Liver cirrhosis, %</td><td align="left" rowspan="1" colspan="1">2.6</td><td align="left" rowspan="1" colspan="1">2.6</td><td align="left" rowspan="1" colspan="1">0.852</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Deficiency anemia, %</td><td align="left" rowspan="1" colspan="1">8.2</td><td align="left" rowspan="1" colspan="1">9.0</td><td align="left" rowspan="1" colspan="1">0.051</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Malnutrition, %</td><td align="left" rowspan="1" colspan="1">7.8</td><td align="left" rowspan="1" colspan="1">8.4</td><td align="left" rowspan="1" colspan="1">0.182</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Depression, %</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">0.042</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Dementia, %</td><td align="left" rowspan="1" colspan="1">5.5</td><td align="left" rowspan="1" colspan="1">4.7</td><td align="left" rowspan="1" colspan="1">0.025</td></tr><tr><td align="left" colspan="4" rowspan="1">Hospital characteristics</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Academic medical center, %</td><td align="left" rowspan="1" colspan="1">70.0</td><td align="left" rowspan="1" colspan="1">65.6</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hospital rural location, %</td><td align="left" rowspan="1" colspan="1">3.1</td><td align="left" rowspan="1" colspan="1">2.9</td><td align="left" rowspan="1" colspan="1">0.453</td></tr><tr><td align="left" style="padding-left:10%" colspan="3" rowspan="1">Hospital bed size, %</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&lt;200 beds</td><td align="left" rowspan="1" colspan="1">6.9</td><td align="left" rowspan="1" colspan="1">4.0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">200&#8211;499 beds</td><td align="left" rowspan="1" colspan="1">23.9</td><td align="left" rowspan="1" colspan="1">22.1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">500&#8211;700 beds</td><td align="left" rowspan="1" colspan="1">30.4</td><td align="left" rowspan="1" colspan="1">31.1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&gt;700 beds</td><td align="left" rowspan="1" colspan="1">38.8</td><td align="left" rowspan="1" colspan="1">42.8</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" colspan="3" rowspan="1">Hospital region, %</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Midwest</td><td align="left" rowspan="1" colspan="1">34.0</td><td align="left" rowspan="1" colspan="1">35.5</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Northeast</td><td align="left" rowspan="1" colspan="1">22.0</td><td align="left" rowspan="1" colspan="1">19.3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">South</td><td align="left" rowspan="1" colspan="1">29.7</td><td align="left" rowspan="1" colspan="1">25.9</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">West</td><td align="left" rowspan="1" colspan="1">14.3</td><td align="left" rowspan="1" colspan="1">19.3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Encounter information</td></tr><tr><td align="left" style="padding-left:10%" colspan="3" rowspan="1">Year of index encounter, %</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">2016</td><td align="left" rowspan="1" colspan="1">11.0</td><td align="left" rowspan="1" colspan="1">11.3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">2017</td><td align="left" rowspan="1" colspan="1">13.1</td><td align="left" rowspan="1" colspan="1">11.6</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">2018</td><td align="left" rowspan="1" colspan="1">13.5</td><td align="left" rowspan="1" colspan="1">11.2</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">2019</td><td align="left" rowspan="1" colspan="1">13.2</td><td align="left" rowspan="1" colspan="1">12.7</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">2020</td><td align="left" rowspan="1" colspan="1">13.5</td><td align="left" rowspan="1" colspan="1">13.4</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">14.5</td><td align="left" rowspan="1" colspan="1">14.6</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">14.1</td><td align="left" rowspan="1" colspan="1">17.3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">7.2</td><td align="left" rowspan="1" colspan="1">7.9</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">Encounter type, %</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Inpatient</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">Insurance, %</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Medicare</td><td align="left" rowspan="1" colspan="1">72.0</td><td align="left" rowspan="1" colspan="1">72.7</td><td align="left" rowspan="1" colspan="1">0.336</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Medicaid</td><td align="left" rowspan="1" colspan="1">5.9</td><td align="left" rowspan="1" colspan="1">5.9</td><td align="left" rowspan="1" colspan="1">0.989</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Commercial</td><td align="left" rowspan="1" colspan="1">16.5</td><td align="left" rowspan="1" colspan="1">16.0</td><td align="left" rowspan="1" colspan="1">0.340</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Military</td><td align="left" rowspan="1" colspan="1">2.3</td><td align="left" rowspan="1" colspan="1">2.4</td><td align="left" rowspan="1" colspan="1">0.610</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Self&#8208;pay</td><td align="left" rowspan="1" colspan="1">1.6</td><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">0.743</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Others</td><td align="left" rowspan="1" colspan="1">1.8</td><td align="left" rowspan="1" colspan="1">1.6</td><td align="left" rowspan="1" colspan="1">0.380</td></tr><tr><td align="left" colspan="4" rowspan="1">Procedural information</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">Stent type, %</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Drug&#8208;eluting stent</td><td align="left" rowspan="1" colspan="1">95.7</td><td align="left" rowspan="1" colspan="1">95.3</td><td align="left" rowspan="1" colspan="1">0.281</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Bare&#8208;metal stent</td><td align="left" rowspan="1" colspan="1">5.0</td><td align="left" rowspan="1" colspan="1">5.6</td><td align="left" rowspan="1" colspan="1">0.142</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Balloon angioplasty, %</td><td align="left" rowspan="1" colspan="1">8.3</td><td align="left" rowspan="1" colspan="1">8.0</td><td align="left" rowspan="1" colspan="1">0.419</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Multivessel intervention, %</td><td align="left" rowspan="1" colspan="1">26.0</td><td align="left" rowspan="1" colspan="1">24.2</td><td align="left" rowspan="1" colspan="1">0.013</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Intravascular imaging, %</td><td align="left" rowspan="1" colspan="1">18.2</td><td align="left" rowspan="1" colspan="1">16.5</td><td align="left" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" colspan="4" rowspan="1">Antithrombotic drugs</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Antiplatelet, %</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Aspirin</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">16.4</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">P2Y12 inhibitor</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">83.6</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Clopidogrel</td><td align="left" rowspan="1" colspan="1">62.5</td><td align="left" rowspan="1" colspan="1">56.7</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Ticagrelor</td><td align="left" rowspan="1" colspan="1">37.3</td><td align="left" rowspan="1" colspan="1">25.6</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Prasugrel</td><td align="left" rowspan="1" colspan="1">3.1</td><td align="left" rowspan="1" colspan="1">3.2</td><td align="left" rowspan="1" colspan="1">0.548</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Anticoagulant, %</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Direct oral anticoagulant</td><td align="left" rowspan="1" colspan="1">45.9</td><td align="left" rowspan="1" colspan="1">54.8</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Rivaroxaban</td><td align="left" rowspan="1" colspan="1">7.3</td><td align="left" rowspan="1" colspan="1">8.6</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Apixaban</td><td align="left" rowspan="1" colspan="1">37.9</td><td align="left" rowspan="1" colspan="1">45.4</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Edoxaban</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Dabigatran</td><td align="left" rowspan="1" colspan="1">1.1</td><td align="left" rowspan="1" colspan="1">1.4</td><td align="left" rowspan="1" colspan="1">0.032</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Vitamin K antagonist</td><td align="left" rowspan="1" colspan="1">15.1</td><td align="left" rowspan="1" colspan="1">14.3</td><td align="left" rowspan="1" colspan="1">0.127</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Unfractionated heparin</td><td align="left" rowspan="1" colspan="1">61.6</td><td align="left" rowspan="1" colspan="1">52.8</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Low&#8208;molecular&#8208;weight heparin</td><td align="left" rowspan="1" colspan="1">21.5</td><td align="left" rowspan="1" colspan="1">17.3</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="4" rowspan="1">Other medications</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">ACE inhibitor, %</td><td align="left" rowspan="1" colspan="1">38.7</td><td align="left" rowspan="1" colspan="1">32.3</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Angiotensin receptor blocker, %</td><td align="left" rowspan="1" colspan="1">20.6</td><td align="left" rowspan="1" colspan="1">20.6</td><td align="left" rowspan="1" colspan="1">0.990</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">ARNI, %</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#946;&#8208;Blocker, %</td><td align="left" rowspan="1" colspan="1">90.0</td><td align="left" rowspan="1" colspan="1">85.8</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Statin, %</td><td align="left" rowspan="1" colspan="1">93.7</td><td align="left" rowspan="1" colspan="1">88.6</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Ezetimibe, %</td><td align="left" rowspan="1" colspan="1">3.9</td><td align="left" rowspan="1" colspan="1">4.4</td><td align="left" rowspan="1" colspan="1">0.111</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">SGLT2 inhibitor, %</td><td align="left" rowspan="1" colspan="1">2.8</td><td align="left" rowspan="1" colspan="1">3.2</td><td align="left" rowspan="1" colspan="1">0.169</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Fondaparinux, %</td><td align="left" rowspan="1" colspan="1">0.2</td><td align="left" rowspan="1" colspan="1">0.2</td><td align="left" rowspan="1" colspan="1">0.793</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Bivalirudin, %</td><td align="left" rowspan="1" colspan="1">14.4</td><td align="left" rowspan="1" colspan="1">14.9</td><td align="left" rowspan="1" colspan="1">0.358</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Glycoprotein IIb/IIIa inhibitor, %</td><td align="left" rowspan="1" colspan="1">17.1</td><td align="left" rowspan="1" colspan="1">15.3</td><td align="left" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">NSAID, %</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Histamine H2 antagonist, %</td><td align="left" rowspan="1" colspan="1">24.8</td><td align="left" rowspan="1" colspan="1">23.4</td><td align="left" rowspan="1" colspan="1">0.032</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Sotalol, %</td><td align="left" rowspan="1" colspan="1">2.1</td><td align="left" rowspan="1" colspan="1">2.2</td><td align="left" rowspan="1" colspan="1">0.742</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Proton pump inhibitor, %</td><td align="left" rowspan="1" colspan="1">55.9</td><td align="left" rowspan="1" colspan="1">55.6</td><td align="left" rowspan="1" colspan="1">0.727</td></tr><tr><td align="left" colspan="4" rowspan="1">Laboratory tests</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hemoglobin, median (IQR), g/dL</td><td align="left" rowspan="1" colspan="1">12.6 (3.3)</td><td align="left" rowspan="1" colspan="1">12.6 (3.4)</td><td align="left" rowspan="1" colspan="1">0.448</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Platelet, median (IQR), per nL</td><td align="left" rowspan="1" colspan="1">214 (94)</td><td align="left" rowspan="1" colspan="1">214 (95)</td><td align="left" rowspan="1" colspan="1">0.490</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Serum creatinine, median (IQR), mg/dL</td><td align="left" rowspan="1" colspan="1">1.1 (0.7)</td><td align="left" rowspan="1" colspan="1">1.1 (0.7)</td><td align="left" rowspan="1" colspan="1">0.208</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">GFR, median (IQR), mL/min&#8201;per&#8201;1.73&#8201;m<sup>2</sup>
</td><td align="left" rowspan="1" colspan="1">60 (29)</td><td align="left" rowspan="1" colspan="1">60 (30)</td><td align="left" rowspan="1" colspan="1">0.022</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Potassium, median (IQR), mEq/L</td><td align="left" rowspan="1" colspan="1">4.1 (0.7)</td><td align="left" rowspan="1" colspan="1">4.1 (0.7)</td><td align="left" rowspan="1" colspan="1">0.428</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prothrombin time, median (IQR), s</td><td align="left" rowspan="1" colspan="1">14.1 (3.5)</td><td align="left" rowspan="1" colspan="1">14.2 (4.3)</td><td align="left" rowspan="1" colspan="1">0.118</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">INR, median (IQR)</td><td align="left" rowspan="1" colspan="1">1.2 (0.3)</td><td align="left" rowspan="1" colspan="1">1.2 (0.3)</td><td align="left" rowspan="1" colspan="1">0.002</td></tr></tbody></table><table-wrap-foot id="jah310564-ntgp-0002"><fn id="jah310564-note-0004"><p>ACE indicates angiotensin&#8208;converting enzyme; ARNI, angiotensin receptor&#8208;neprilysin inhibitor; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; INR, International Normalized Ratio; IQR, interquartile range; NA, not applicable; PCI, percutaneous coronary intervention; P2Y12, purinergic receptor P2Y, G&#8208;protein coupled, 12 protein; and SGLT2, sodium&#8208;glucose cotransporter&#8208;2.</p></fn><fn id="jah310564-note-0444"><label>*</label><p>Other races include unknown, unavailable, declined, and miscellaneous races.</p></fn></table-wrap-foot></table-wrap><p>For the purposes of this study, patients without medication data (31.5%) were excluded. Patients with AF who underwent PCI for myocardial infarction were divided into 2 groups based on the antithrombotic regimen received the day after PCI; the triple therapy group received aspirin, a P2Y12 (purinergic receptor P2Y, G&#8208;protein coupled, 12 protein) inhibitor (clopidogrel, ticagrelor, prasugrel), and an anticoagulant (rivaroxaban, apixaban, edoxaban, dabigatran, warfarin, heparin), whereas the double therapy group received either aspirin or a P2Y12 inhibitor with an anticoagulant.</p></sec><sec id="jah310564-sec-0011"><title>Outcomes of Interest</title><p>The primary outcome was in&#8208;hospital mortality, with secondary outcomes including stent thrombosis, major bleeding, intracranial hemorrhage (ICH), and net clinical adverse events (NACEs). Major bleeding was defined according to the definition from TIMI (Thrombolysis In Myocardial Infarction).<xref rid="jah310564-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> NACEs were a composite outcome consisting of all the primary and secondary outcomes. Urinary tract infection and pneumonia were selected as falsification end points.<xref rid="jah310564-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>
</p></sec><sec id="jah310564-sec-0012"><title>Statistical Analysis</title><p>The baseline characteristics of the study population are summarized in Table&#160;<xref rid="jah310564-tbl-0001" ref-type="table">1</xref>. All of the covariates were categorical, so they were summarized using percentages then compared using &#967;<sup>2</sup> tests. Outcomes were compared with odds ratios from both univariable and multivariable logistic regression adjusted for sex, race, clinical presentation (ST&#8208;segment&#8211;elevation myocardial infarction [STEMI] or non&#8208;STEMI), select comorbidities (diabetes, congestive heart failure, valvular heart disease, peripheral artery disease, prior PCI, prior coronary artery bypass graft, prior stroke, chronic kidney disease, liver cirrhosis, deficiency anemia, malnutrition, dementia), hospital characteristics (academic medical center, hospital region, hospital bed size), year of encounter, insurance, procedures (stent type, balloon angioplasty, multivessel intervention, intravascular imaging), and pertinent medications (statin, glycoprotein IIb/IIIa inhibitor, histamine H2 blocker, proton pump inhibitor, ticagrelor, and vitamin K antagonist). As a sensitivity analysis, we also performed inverse probability of treatment weighting (IPTW) accounting for the same covariates to compare the same outcomes. In short, IPTW calculates the probability of receiving triple therapy with propensity scores that are used to assign weights.<xref rid="jah310564-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Once weights are applied, a pseudo&#8208;population is created in which the treatment assignment (triple versus double therapy) is independent of baseline covariates, resulting in pseudo&#8208;randomization. Standard mean difference &lt;0.10 after IPTW was deemed an appropriate balance.<xref rid="jah310564-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> A love plot and density plot were also drawn to illustrate the quality of the IPTW. A 2&#8208;sided <italic toggle="yes">P</italic> value &lt;0.05 was considered statistically significant. Data curation and statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC), and IPTW was conducted using R version 4.4 (R Foundation for Statistical Computing, Vienna, Austria).</p></sec></sec><sec sec-type="results" id="jah310564-sec-0013"><title>RESULTS</title><p>A total of 29&#8201;226 patients were included (67.3% men), with 4777 (16.3%) receiving an immediate transition to double therapy and 24&#8201;449 (83.7%) receiving an initial course of triple therapy. Fewer patients &lt;65&#8201;years of age were immediately transitioned to double therapy (22.7% versus 25.1%, <italic toggle="yes">P</italic>=0.001) (Table&#160;<xref rid="jah310564-tbl-0001" ref-type="table">1</xref>). Fewer patients in the initial double therapy group underwent PCI for STEMI than the initial triple therapy group (36.9% versus 42.6%, <italic toggle="yes">P</italic>&lt;0.001). No significant differences were observed in sex, comorbidities, prior PCI (1.7% versus 1.5%, <italic toggle="yes">P</italic>=0.444), insurance, and stent type. Multivessel intervention (24.2% versus 26.0%, <italic toggle="yes">P</italic>=0.013) and intravascular imaging (16.5% versus 18.2%, <italic toggle="yes">P</italic>=0.007) were less frequent in those immediately transitioned to double therapy. Baseline hemoglobin, platelet, creatinine, and prothrombin time were not different between the groups. Median hospital stay was 6&#8201;days.</p><p>On unadjusted analysis, no difference in in&#8208;hospital mortality, major bleeding, ICH, and NACEs between those immediately transitioned to double therapy versus triple therapy was found (<xref rid="jah310564-fig-0001" ref-type="fig">Figure</xref>). However, immediate transition to double therapy was associated with higher risk of stent thrombosis compared with triple therapy (1.1% versus 0.8%; odds ratio [OR], 1.48 [95% CI, 1.001&#8211;1.85]). After adjustment, there was no difference in in&#8208;hospital mortality (9.4% versus 9.2%; adjusted OR [aOR], 1.05 [95% CI, 0.93&#8211;1.18]), major bleeding (5.7% versus 5.4%; aOR, 1.13 [95% CI, 0.97&#8211;1.32]), ICH (0.7% versus 0.6%; aOR, 1.19 [95% CI, 0.81&#8211;1.75]), and NACEs (13.4% versus 12.8%; aOR, 1.10 [95% CI, 0.99&#8211;1.21]) between those immediately transitioned to double therapy and those treated with initial triple therapy. Falsification end points urinary tract infection (aOR, 1.08 [95% CI, 0.91&#8211;1.29]; <italic toggle="yes">P</italic>=0.361) and pneumonia (aOR, 1.13 [95% CI, 0.98&#8211;1.29]; <italic toggle="yes">P</italic>=0.072) were also no different. However, immediate transition to double therapy was associated with higher odds of stent thrombosis (1.1% versus 0.8%; aOR, 1.48 [95% CI, 1.08&#8211;2.03]).</p><fig position="float" fig-type="Figure" id="jah310564-fig-0001" orientation="portrait"><label>Figure 1</label><caption><title>Comparison of in&#8208;hospital outcomes between double and triple therapy.</title><p>The figure shows the odds ratio of in&#8208;hospital outcomes after double therapy compared with triple therapy. The vertical line represents the adjusted odds ratio, whereas the horizontal line represents the 95% CI. The sizes of the blue squares are inversely proportional to the width of the 95% CI. Covariates accounted for in the statistical models include clinical presentation, age, sex, race, diabetes, congestive heart failure, valvular heart disease, peripheral artery disease, prior PCI, prior coronary artery bypass graft, prior stroke, chronic kidney disease, liver cirrhosis, deficiency anemia, malnutrition, dementia, academic medical center, hospital region, hospital bed size, year of encounter, insurance, drug type, multivessel intervention, intravascular imaging, statin, glycoprotein IIb/IIIa inhibitor, histamine H2 blocker, proton pump inhibitor, ticagrelor, and vitamin K antagonist. IPTW indicates inverse probability of treatment weighting; OR, odds ratio; and PCI, percutaneous coronary intervention.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="JAH3-14-e038589-g001.jpg"/></fig><p>Among 12&#8201;183 patients with STEMI, 1762 (14.5%) patients were immediately transitioned to double therapy, and among 17&#8201;043 patients with non&#8208;STEMI, 3015 (17.7%) patients were immediately transitioned to double therapy. Subgroup analysis showed no difference in in&#8208;hospital mortality, major bleeding, and ICH between initial double and initial triple therapy in STEMI and non&#8208;STEMI, but immediate transition to double therapy was associated with higher odds of stent thrombosis (2.0% versus 1.3%; aOR, 1.46 [95% CI, 1.001&#8211;2.13]) and NACEs (22.1% versus 17.5%; aOR, 1.17 [95% CI, 1.01&#8211;1.34]) in STEMI (Table&#160;<xref rid="jah310564-tbl-0002" ref-type="table">2</xref>). Subgroup analysis in patients with and without prior PCI and with and without prior myocardial infarction each showed similar outcomes as the original analysis. The quality of the IPTW analysis was appropriate, as indicated by all weighted covariates having standardized mean differences &lt;0.10 (Table&#160;<xref rid="jah310564-supitem-0001" ref-type="supplementary-material">S3</xref>). The love plot showed appropriate balance for all covariates, and the density plot showed a visually appropriate overlap in the propensity scores used to conduct IPTW (Figures&#160;<xref rid="jah310564-supitem-0001" ref-type="supplementary-material">S1</xref> and <xref rid="jah310564-supitem-0001" ref-type="supplementary-material">S2</xref>). IPTW analysis showed similar results in all outcomes, including higher odds of stent thrombosis (aOR, 1.54 [95% CI, 1.09&#8211;2.17]), between double and triple therapy.</p><table-wrap position="float" id="jah310564-tbl-0002" content-type="Table" orientation="portrait"><label>Table 2</label><caption><p>Subgroup Analysis According to Clinical Presentation</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Presentation</th><th align="left" rowspan="1" colspan="1">Outcome<xref rid="jah310564-note-0006" ref-type="table-fn">*</xref>
</th><th align="left" rowspan="1" colspan="1">Triple</th><th align="left" rowspan="1" colspan="1">Double</th><th align="left" rowspan="1" colspan="1">Adjusted odds ratio</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="6" colspan="1">STEMI</td><td align="left" rowspan="1" colspan="1">Sample size</td><td align="left" rowspan="1" colspan="1">10&#8201;421</td><td align="left" rowspan="1" colspan="1">1762</td><td align="left" rowspan="1" colspan="1">&#8230;</td><td align="left" rowspan="1" colspan="1">&#8230;</td></tr><tr><td align="left" rowspan="1" colspan="1">In&#8208;hospital mortality (%)</td><td align="left" rowspan="1" colspan="1">12.6</td><td align="left" rowspan="1" colspan="1">15.3</td><td align="left" rowspan="1" colspan="1">1.06 (0.90&#8211;1.25)</td><td align="left" rowspan="1" colspan="1">0.457</td></tr><tr><td align="left" rowspan="1" colspan="1">Stent thrombosis (%)</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">2.0</td><td align="left" rowspan="1" colspan="1">1.46 (1.001&#8211;2.13)</td><td align="left" rowspan="1" colspan="1">0.049</td></tr><tr><td align="left" rowspan="1" colspan="1">Major bleeding (%)</td><td align="left" rowspan="1" colspan="1">7.3</td><td align="left" rowspan="1" colspan="1">9.7</td><td align="left" rowspan="1" colspan="1">1.24 (0.99&#8211;1.52)</td><td align="left" rowspan="1" colspan="1">0.051</td></tr><tr><td align="left" rowspan="1" colspan="1">Intracranial hemorrhage (%)</td><td align="left" rowspan="1" colspan="1">0.9</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">1.25 (0.75&#8211;2.06)</td><td align="left" rowspan="1" colspan="1">0.394</td></tr><tr><td align="left" rowspan="1" colspan="1">Net adverse clinical events (%)</td><td align="left" rowspan="1" colspan="1">17.5</td><td align="left" rowspan="1" colspan="1">22.1</td><td align="left" rowspan="1" colspan="1">1.17 (1.01&#8211;1.34)</td><td align="left" rowspan="1" colspan="1">0.031</td></tr><tr><td align="left" rowspan="6" colspan="1">NSTEMI</td><td align="left" rowspan="1" colspan="1">Sample size</td><td align="left" rowspan="1" colspan="1">14&#8201;028</td><td align="left" rowspan="1" colspan="1">3015</td><td align="left" rowspan="1" colspan="1">&#8230;</td><td align="left" rowspan="1" colspan="1">&#8230;</td></tr><tr><td align="left" rowspan="1" colspan="1">In&#8208;hospital mortality (%)</td><td align="left" rowspan="1" colspan="1">6.6</td><td align="left" rowspan="1" colspan="1">6.0</td><td align="left" rowspan="1" colspan="1">1.01 (0.85&#8211;1.20)</td><td align="left" rowspan="1" colspan="1">0.917</td></tr><tr><td align="left" rowspan="1" colspan="1">Stent thrombosis (%)</td><td align="left" rowspan="1" colspan="1">0.4</td><td align="left" rowspan="1" colspan="1">0.5</td><td align="left" rowspan="1" colspan="1">1.38 (0.78&#8211;2.46)</td><td align="left" rowspan="1" colspan="1">0.269</td></tr><tr><td align="left" rowspan="1" colspan="1">Major bleeding (%)</td><td align="left" rowspan="1" colspan="1">3.9</td><td align="left" rowspan="1" colspan="1">3.4</td><td align="left" rowspan="1" colspan="1">0.96 (0.75&#8211;1.22)</td><td align="left" rowspan="1" colspan="1">0.734</td></tr><tr><td align="left" rowspan="1" colspan="1">Intracranial hemorrhage (%)</td><td align="left" rowspan="1" colspan="1">0.4</td><td align="left" rowspan="1" colspan="1">0.4</td><td align="left" rowspan="1" colspan="1">1.07 (0.56&#8211;2.03)</td><td align="left" rowspan="1" colspan="1">0.843</td></tr><tr><td align="left" rowspan="1" colspan="1">Net adverse clinical events (%)</td><td align="left" rowspan="1" colspan="1">9.3</td><td align="left" rowspan="1" colspan="1">8.4</td><td align="left" rowspan="1" colspan="1">0.99 (0.85&#8211;1.15)</td><td align="left" rowspan="1" colspan="1">0.903</td></tr></tbody></table><table-wrap-foot id="jah310564-ntgp-0003"><fn id="jah310564-note-0005"><p>NSTEMI indicates non&#8211;ST&#8208;segment&#8211;elevation myocardial infarction; and STEMI, ST&#8208;segment&#8211;elevation myocardial infarction.</p></fn><fn id="jah310564-note-0006"><label>*</label><p>Comparisons are made with double therapy as the reference.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion" id="jah310564-sec-0014"><title>DISCUSSION</title><p>In the largest contemporary analysis of practice patterns in anticoagulation and antiplatelet use following PCI in patients with AF to date, we found that &gt;15% of patients with AF were prescribed double therapy immediately on day 1 following PCI rather than undergoing a short course of triple therapy. Immediate transition to double therapy was associated with similar in&#8208;hospital mortality, major bleeding, ICH, and NACEs compared with those receiving an initial course of triple therapy post&#8208;PCI, although we did observe a signal for a slightly higher incidence of stent thrombosis (absolute difference 0.3%) in those transitioning to a single antiplatelet agent on day 1 post&#8208;PCI. This higher risk appeared to be driven by patients with STEMI. Although an immediate double therapy approach appears safe in select patients, randomized controlled trials are required to definitively answer this question.</p><p>All randomized trials comparing double and triple therapy to date have mandated a short course of triple therapy before transitioning to double therapy, with most requiring at least 30&#8201;days.<xref rid="jah310564-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="jah310564-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="jah310564-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="jah310564-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> The AUGUSTUS (Antithrombotic Therapy After Acute Coronary Syndrome or PCI in Atrial Fibrillation) trial was the only exception, with an average triple therapy duration of 6.5&#177;4.1&#8201;days.<xref rid="jah310564-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Although the AUGUSTUS trial was not powered to assess for coronary ischemic events, it did report more of these events in the double therapy group, a trend seen in other trials as well.<xref rid="jah310564-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Our study is the first to investigate outcomes in patient with AF started immediately on double therapy following PCI, finding that &gt;15% receive this therapeutic approach in contemporary clinical practice, despite the lack of randomized trials testing this strategy.</p><p>Although statistically nonsignificant, nearly all the point estimates in our study favored an initial course of triple therapy, and more studies will be needed to examine whether such concern is valid. We observed a small but statistically significant increase in stent thrombosis among those receiving immediate double therapy, driven by a difference in patients with STEMI. This difference was preserved even after IPTW was performed, suggesting stronger evidence. A trend toward increased risk of stent thrombosis in patients receiving double therapy was observed in some, but not all, randomized trials on this topic.<xref rid="jah310564-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="jah310564-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="jah310564-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> However, meta&#8208;analyses have found that the modest increase in ischemic risk is generally outweighed by the significant reduction in bleeding risk.<xref rid="jah310564-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="jah310564-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="jah310564-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> This suggests that the highest risk subgroup of patients, such as those presenting with STEMI, may benefit from an initial course of triple therapy before transitioning to double therapy.</p><p>The strengths of our study include a large sample size from &gt;1000 US hospitals. However, its limitations include the observational design, which may introduce confounding and bias when attempting to draw conclusions around causal inference. Additionally, 31.5% of patients were excluded due to missing medication data, which could introduce selection bias. The complexity of intervened lesions, severity of comorbid conditions, and duration of triple therapy were not accounted for in our analysis because of lack of granular details. Our findings should also be interpreted after considering that there may be a competing risk of death, our primary outcome, on secondary outcomes.</p><p>In conclusion, many cardiologists are transitioning their patients with AF to double therapy immediately following PCI, despite the lack of randomized controlled evidence for this approach. Our study suggests that this is likely safe for select patients with AF following PCI. However, we observed a signal for increased risk of stent thrombosis with immediate double therapy in select populations, specifically those presenting with STEMI. This suggests that the highest risk subgroups of patients likely benefit from an initial course of triple therapy before transitioning to double therapy. Future randomized trials are needed to determine which patients require an initial short course of triple therapy before transitioning to double therapy in patients with AF post&#8208;PCI and, if so, to establish the optimal duration.</p></sec><sec id="jah310564-sec-0015"><title>Sources of Funding</title><p>None.</p></sec><sec sec-type="COI-statement" id="jah310564-sec-0016"><title>Disclosures</title><p>Dr Nanna reports current research support from the American College of Cardiology Foundation supported by the George F. and Ann Harris Bellows Foundation, the Patient&#8208;Centered Outcomes Research Institute, the Yale Claude D. Pepper Older Americans Independence Center (P30AG021342), and the National Institute on Aging from K76AG088428. Dr Nanna also reports being a consultant for Heartflow, Novo Nordisk, and Merck. The remaining authors have no disclosures to report.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="jah310564-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Tables S1&#8211;S3</p><p>Figures&#160;S1&#8211;S2</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="JAH3-14-e038589-s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ref-list content-type="cited-references" id="jah310564-bibl-0001"><title>REFERENCES</title><ref id="jah310564-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jah310564-cit-0001"><string-name name-style="western"><surname>Kistler</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Sanders</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Fynn</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Stevenson</surname><given-names>IH</given-names></string-name>, <string-name name-style="western"><surname>Spence</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Vohra</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Sparks</surname><given-names>PB</given-names></string-name>, <string-name name-style="western"><surname>Kalman</surname><given-names>JM</given-names></string-name>. <article-title>Electrophysiologic and electroanatomic changes in the human atrium associated with age</article-title>. <source>J Am Coll Cardiol</source>. <year>2004</year>;<volume>44</volume>:<fpage>109</fpage>&#8211;<lpage>116</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2004.03.044</pub-id><pub-id pub-id-type="pmid">15234418</pub-id></mixed-citation></ref><ref id="jah310564-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jah310564-cit-0002"><string-name name-style="western"><surname>January</surname><given-names>CT</given-names></string-name>, <string-name name-style="western"><surname>Wann</surname><given-names>LS</given-names></string-name>, <string-name name-style="western"><surname>Alpert</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Calkins</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Cigarroa</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Cleveland</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Conti</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Ellinor</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Ezekowitz</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Field</surname><given-names>ME</given-names></string-name>, et&#160;al. <article-title>2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation</article-title>. <source>Circulation</source>. <year>2014</year>;<volume>130</volume>:<fpage>e199</fpage>&#8211;<lpage>e267</lpage>. doi: <pub-id pub-id-type="doi">10.1161/cir.0000000000000041</pub-id><pub-id pub-id-type="pmid">24682347</pub-id><pub-id pub-id-type="pmcid">PMC4676081</pub-id></mixed-citation></ref><ref id="jah310564-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jah310564-cit-0003"><string-name name-style="western"><surname>Sullivan</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Nanna</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Rao</surname><given-names>SV</given-names></string-name>, <string-name name-style="western"><surname>Cantell</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gibson</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Verheugt</surname><given-names>FWA</given-names></string-name>, <string-name name-style="western"><surname>Peterson</surname><given-names>ED</given-names></string-name>, <string-name name-style="western"><surname>Lopes</surname><given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Alexander</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Granger</surname><given-names>CB</given-names></string-name>, et&#160;al. <article-title>A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention</article-title>. <source>Cathet Cardio Intervent</source>. <year>2020</year>;<volume>96</volume>:<fpage>E109</fpage>. doi: <pub-id pub-id-type="doi">10.1002/ccd.28535</pub-id><pub-id pub-id-type="pmcid">PMC7211549</pub-id><pub-id pub-id-type="pmid">31713326</pub-id></mixed-citation></ref><ref id="jah310564-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jah310564-cit-0004"><string-name name-style="western"><surname>Gibson</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Mehran</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bode</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Halperin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Verheugt</surname><given-names>FW</given-names></string-name>, <string-name name-style="western"><surname>Wildgoose</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Birmingham</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ianus</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Burton</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>van Eickels</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Prevention of bleeding in patients with atrial fibrillation undergoing PCI</article-title>. <source>N Engl J Med</source>. <year>2016</year>;<volume>375</volume>:<fpage>2423</fpage>&#8211;<lpage>2434</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1611594</pub-id><pub-id pub-id-type="pmid">27959713</pub-id></mixed-citation></ref><ref id="jah310564-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jah310564-cit-0005"><string-name name-style="western"><surname>Lopes</surname><given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Heizer</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Aronson</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Vora</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Massaro</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Mehran</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Goodman</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Windecker</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Darius</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation</article-title>. <source>N Engl J Med</source>. <year>2019</year>;<volume>380</volume>:<fpage>1509</fpage>&#8211;<lpage>1524</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1817083</pub-id><pub-id pub-id-type="pmid">30883055</pub-id></mixed-citation></ref><ref id="jah310564-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jah310564-cit-0006"><string-name name-style="western"><surname>Cannon</surname><given-names>CP</given-names></string-name>, <string-name name-style="western"><surname>Bhatt</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Oldgren</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lip</surname><given-names>GY</given-names></string-name>, <string-name name-style="western"><surname>Ellis</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Kimura</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Maeng</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Merkely</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zeymer</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Gropper</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation</article-title>. <source>N Engl J Med</source>. <year>2017</year>;<volume>377</volume>:<fpage>1513</fpage>&#8211;<lpage>1524</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1708454</pub-id><pub-id pub-id-type="pmid">28844193</pub-id></mixed-citation></ref><ref id="jah310564-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jah310564-cit-0007"><string-name name-style="western"><surname>Vranckx</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Valgimigli</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Eckardt</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Tijssen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lewalter</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Gargiulo</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Batushkin</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Campo</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Lysak</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Vakaliuk</surname><given-names>I</given-names></string-name>, et&#160;al. <article-title>Edoxaban&#8208;based versus vitamin K antagonist&#8208;based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST&#8208;AF PCI): a randomised, open&#8208;label, phase 3b trial</article-title>. <source>Lancet</source>. <year>2019</year>;<volume>394</volume>:<fpage>1335</fpage>&#8211;<lpage>1343</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(19)31872-0</pub-id><pub-id pub-id-type="pmid">31492505</pub-id></mixed-citation></ref><ref id="jah310564-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jah310564-cit-0008"><string-name name-style="western"><surname>Mehran</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Rao</surname><given-names>SV</given-names></string-name>, <string-name name-style="western"><surname>Bhatt</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Gibson</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Caixeta</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Eikelboom</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kaul</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wiviott</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Menon</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Nikolsky</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium</article-title>. <source>Circulation</source>. <year>2011</year>;<volume>123</volume>:<fpage>2736</fpage>&#8211;<lpage>2747</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.009449</pub-id><pub-id pub-id-type="pmid">21670242</pub-id></mixed-citation></ref><ref id="jah310564-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jah310564-cit-0009"><string-name name-style="western"><surname>Groenwold</surname><given-names>RHH</given-names></string-name>. <article-title>Falsification end points for observational studies</article-title>. <source>JAMA</source>. <year>2013</year>;<volume>309</volume>:<fpage>1769</fpage>&#8211;<lpage>1770</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2013.3089</pub-id><pub-id pub-id-type="pmid">23632712</pub-id></mixed-citation></ref><ref id="jah310564-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jah310564-cit-0010"><string-name name-style="western"><surname>Austin</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Stuart</surname><given-names>EA</given-names></string-name>. <article-title>Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies</article-title>. <source>Stat Med</source>. <year>2015</year>;<volume>34</volume>:<fpage>3661</fpage>&#8211;<lpage>3679</lpage>. doi: <pub-id pub-id-type="doi">10.1002/sim.6607</pub-id><pub-id pub-id-type="pmid">26238958</pub-id><pub-id pub-id-type="pmcid">PMC4626409</pub-id></mixed-citation></ref><ref id="jah310564-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jah310564-cit-0011"><string-name name-style="western"><surname>Chesnaye</surname><given-names>NC</given-names></string-name>, <string-name name-style="western"><surname>Stel</surname><given-names>VS</given-names></string-name>, <string-name name-style="western"><surname>Tripepi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Dekker</surname><given-names>FW</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Zoccali</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Jager</surname><given-names>KJ</given-names></string-name>. <article-title>An introduction to inverse probability of treatment weighting in observational research</article-title>. <source>Clin Kidney J</source>. <year>2022</year>;<volume>15</volume>:<fpage>14</fpage>&#8211;<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.1093/ckj/sfab158</pub-id><pub-id pub-id-type="pmid">35035932</pub-id><pub-id pub-id-type="pmcid">PMC8757413</pub-id></mixed-citation></ref><ref id="jah310564-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jah310564-cit-0012"><string-name name-style="western"><surname>And&#242;</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Costa</surname><given-names>F</given-names></string-name>. <article-title>Double or triple antithrombotic therapy after coronary stenting and atrial fibrillation: a systematic review and meta&#8208;analysis of randomized clinical trials</article-title>. <source>Int J Cardiol</source>. <year>2020</year>;<volume>302</volume>:<fpage>95</fpage>&#8211;<lpage>102</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijcard.2019.12.054</pub-id><pub-id pub-id-type="pmid">31924397</pub-id></mixed-citation></ref><ref id="jah310564-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jah310564-cit-0013"><string-name name-style="western"><surname>Guo</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Hao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Qiang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ruan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>. <article-title>Efficacy and safety of an antithrombotic regimen for atrial fibrillation patients with acute coronary syndrome or those undergoing percutaneous coronary intervention: a meta&#8208;analysis</article-title>. <source>Aging</source>. <year>2020</year>;<volume>12</volume>:<fpage>12930</fpage>&#8211;<lpage>12942</lpage>. doi: <pub-id pub-id-type="doi">10.18632/aging.103359</pub-id><pub-id pub-id-type="pmid">32611835</pub-id><pub-id pub-id-type="pmcid">PMC7377825</pub-id></mixed-citation></ref><ref id="jah310564-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jah310564-cit-0014"><string-name name-style="western"><surname>Gargiulo</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Goette</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tijssen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Eckardt</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lewalter</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Vranckx</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Valgimigli</surname><given-names>M</given-names></string-name>. <article-title>Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta&#8208;analysis of non&#8208;vitamin K antagonist oral anticoagulant&#8208;based randomized clinical trials</article-title>. <source>Eur Heart J</source>. <year>2019</year>;<volume>40</volume>:<fpage>3757</fpage>&#8211;<lpage>3767</lpage>. doi: <pub-id pub-id-type="doi">10.1093/eurheartj/ehz732</pub-id><pub-id pub-id-type="pmid">31651946</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>